Anila Lingamneni - May 16, 2022 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role: EVP, Chief Technology Officer
Signature: /s/ Thomas V. Powers, attorney-in-fact for Ms. Lingamneni
Stock symbol: HAE
Transactions as of: May 16, 2022
Transactions value $: $0
Form type: 4
Date filed: 5/18/2022, 04:57 PM
Previous filing: Apr 19, 2022
Next filing: May 23, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HAE	Common Stock	Award		+4.34K	+30.21%		18.7K	May 16, 2022	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HAE	Non-qualified Stock Option (Right to Buy)	Award	$0	+10.1K		$0.00	10.1K	May 16, 2022	Common Stock	10.1K	$57.60	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
F2	Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3	This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022.
F4	Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.